Viking Therapeutics Presents Results from Ph 2 Study of VK2809 in NAFLD
13 Nov 2018 //
PR NEWSWIRE
Viking Therapeutics Announces VK2809 Phase 2 Study Results
04 Oct 2018 //
PR NEWSWIRE
Viking Therapeutics Announces Pricing of $175.8 Million Public Offering
20 Sep 2018 //
BIOSPACE